A systematic review of 19 studies found that neuropeptide Y (NPY) levels are reduced in Alzheimer's patients and that NPY shows neuroprotective effects in disease models, suggesting potential as both a biomarker and therapeutic target.
19 studies reviewedConsistently showing reduced NPY levels and neuroprotective effects in Alzheimer's models
What the researchers found
NPY levels are reduced in cerebrospinal fluid and plasma of Alzheimer's patients, and NPY demonstrates neuroprotective properties in both in vitro and in vivo AD models.
Why it matters
Early detection of Alzheimer's disease remains a major clinical challenge, and current treatments have limited effectiveness. If NPY can reliably indicate early AD and also protect neurons, it could serve a dual role as both a diagnostic tool and a basis for new therapies.
The numbers in context
NPY is a 36-amino-acid peptide. AD is one of the most common neurodegenerative diseases.
How the study worked
Systematic review of 19 published studies identified through keyword searches for 'Alzheimer's disease and neuropeptide Y' and related terms across scientific databases.
Who was studied
Review of preclinical and clinical Alzheimer's disease research
What this study cannot tell us
Many of the reviewed studies are older and used small sample sizes. Results on NPY levels in AD patients were not entirely consistent (some showed reductions, others no change). Most neuroprotective evidence comes from animal models and cell studies, not human clinical trials.
How to read the evidence
Preliminary evidence based on a systematic review of mostly preclinical and small clinical studies. The neuroprotective findings need validation in larger human trials.
When this study was published
Published in 2024. Reviews literature spanning multiple decades of NPY-Alzheimer's research.
The bigger picture
As the global population ages, Alzheimer's disease is becoming an increasingly urgent health crisis. The search for reliable biomarkers and new therapeutic approaches is critical. NPY's dual potential as a diagnostic marker and neuroprotective agent makes it a particularly promising research target, though more recent clinical studies are needed to confirm these findings.
Questions still open
- Can NPY blood levels reliably distinguish early-stage Alzheimer's from normal aging?
- What is the best route of administration for NPY-based neuroprotective therapy?
- How do NPY levels change across different stages of Alzheimer's disease progression?
Common questions
What is neuropeptide Y and what does it do in the brain?
Could NPY be used to detect Alzheimer's disease early?
Read the original research
The Role of Neuropeptide Y in the Pathogenesis of Alzheimer's Disease: Diagnostic Significance and Neuroprotective Functions.
Neurology international, 16(6), 1318-1331
Citation
Shapovalova, Ksenia; Zorkina, Yana; Abramova, Olga; Andryushchenko, Alisa; Chekhonin, Vladimir; Kostyuk, Georgy. (2024). The Role of Neuropeptide Y in the Pathogenesis of Alzheimer's Disease: Diagnostic Significance and Neuroprotective Functions.. Neurology international, 16(6), 1318-1331. https://doi.org/10.3390/neurolint16060100